FindTrial
Sign In

"Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics study

"Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics study - "Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative" Pharmacodynamics, Pharmacokinetics and Pharmacogenomics study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000006194
Enrollment
1400
Registered
2011-12-01
Start date
2011-09-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female patient with invasive breast cancer

Interventions

Blood and urine collection for pharmacokinetics analysis

Sponsors

Graduate School of Medicine Kyoto University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: Patients who enrolled in "Adjuvant Chemotherapy Trial of S-1 for breast cancer with ER-positive and HER2-negative"

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

MeasureTime frame
Pharmacokinetics of S-1—

Countries

Japan

Contacts

Public ContactHiroshi Ishiguro

Graduate School of Medicine Kyoto University Department of Target Therapy Oncology

hkkishi@kuhp.kyoto-u.ac.jp075-751-4950

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026